Facial Hemangiomas May Signal PHACE

• by Andrea Surnit

• April 14, 2026

IL-17, IL-23 Therapies Lead Psoriasis Care

Network meta-analysis suggests higher PASI 90 response rates with biologics vs oral systemic therapies

• by Andrea Surnit

• April 12, 2026

• 3 min

Atopic Dermatitis Treatment Targets Defined

Consensus definitions for disease control in atopic dermatitis aim to standardize clinical trial end points and support treat-to-target strategies.

• by Kerri Miller

• April 15, 2026

• 5 min

MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics

• by Rocío Maseda, María Carmen Arriba, Lucía Martínez-Santamaría, Eva Jiménez, Sara Herráiz-Gil, Nuria Illera, Lucía Quintana-Castanedo, Marta García, Susana Suárez-Sancho, Rosa Yáñez, Isabel Pérez-Conde, Marta Carretero, Magdalena Martínez-Queipo, Raquel de Paz, Carlos León, Víctor Jiménez-Yuste, Alberto M. Borobia, Ángeles Vicente, Su M. Lwin, John A. McGrath, María Eugenia Fernández-Santos, Nora Butta, Rosa Sacedón, Marcela del Río, Raúl de Lucas, María José Escámez

• May 5, 2026